[go: up one dir, main page]

AR093758A1 - Inhibidores de aril lactama quinasa - Google Patents

Inhibidores de aril lactama quinasa

Info

Publication number
AR093758A1
AR093758A1 ARP130102716A ARP130102716A AR093758A1 AR 093758 A1 AR093758 A1 AR 093758A1 AR P130102716 A ARP130102716 A AR P130102716A AR P130102716 A ARP130102716 A AR P130102716A AR 093758 A1 AR093758 A1 AR 093758A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
haloalkyl
3amino
cycloalkyl
Prior art date
Application number
ARP130102716A
Other languages
English (en)
Inventor
M Vrudhula Vivekananda
Pan Senliang
Rajamani Ramkumar
Jethanand Nara Susheel
Sivasamban Karatholuvhu Maheswaran
Kumar Maishal Tarun
L Ditta Jonathan
Diane Dzierba Carolyn
J Bronson Joanne
E Macor John
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR093758A1 publication Critical patent/AR093758A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde R¹ se selecciona de hidrógeno, alquenilo C₂₋₄, alcoxi C₁₋₃, alcoxi C₁₋₃alquilo C₁₋₃, alquilo C₁₋₃, alquil C₁₋₃amino, arilalquilo C₁₋₃, cicloalquilo C₃₋₆, cicloalquil C₃₋₆alquilo C₁₋₃, haloalquilo C₁₋₃ y hidroxialquilo C₁₋₃; R² se selecciona de hidrógeno, alcoxi C₁₋₃, alcoxi C₁₋₃carbonilamino, alquilo C₁₋₃, alquil C₁₋₃amino, alquil C₁₋₃carbonilamino, amino, arilamino, arilcarbonilamino, cicloalquil C₃₋₆amino, cicloalquil C₃₋₆carbonilamino, cicloalquiloxi C₃₋₆, halo, haloalcoxi C₁₋₃, haloalquilo C₁₋₃, haloalquil C₂₋₃amino, haloalquil C₂₋₃carbonilamino, hidroxi y fenil-alquil C₁₋₃amino, en donde el fenilo se sustituye opcionalmente con un grupo alcoxi C₁₋₃; R³ y R⁴ se seleccionan independientemente de hidrógeno, alcoxi C₁₋₄, alcoxi C₁₋₃alquilo C₁₋₃, alcoxi C₁₋₃carbonilo, alquilo C₁₋₄, alquil C₁₋₃sulfonilo, aminocarbonilo, ciano, cicloalquilo C₃₋₆, di(alquil C₁₋₃)aminocarbonilo, halo, haloalcoxi C₁₋₃, haloalquilo C₁₋₃, heteroarilo, hidroxi, hidroxialquilo C₁₋₃ y fenilo opcionalmente sustituido con un grupo halo; R⁵ es alquil C₁₋₃-Y o alquilo C₂₋₈, en donde alquilo C₂₋₈ se sustituye opcionalmente con 1, 2, 3 ó 4 grupos seleccionados independientemente de alcoxi C₁₋₃, alquil C₁₋₃amino, alcoxi C₁₋₃alquil C₂₋₃amino, amino, arilo, di(alquil C₁₋₃)amino, halo, haloalquil C₁₋₃amino, haloalquil C₁₋₃carbonilamino, hidroxi, -NRˣRʸ y cicloalquilo C₃₋₈, en donde el cicloalquilo también se sustituye opcionalmente con 1, 2 ó 3 grupos seleccionado independientemente de alcoxi C₁₋₃, alquilo C₁₋₃, alquil C₁₋₃amino, alcoxi C₁₋₃alquil C₂₋₃amino, amino, arilo, arilalquilo C₁₋₃, halo, haloalquilo C₁₋₃, haloalquil C₁₋₃amino e hidroxi; Rˣ y Rʸ, junto con el átomo de nitrógeno al que están unidos, forman un anillo de 3 a 6 miembros; e Y se selecciona del grupo de fórmulas (2); en donde n es 0, 1, 2 ó 3; cada R⁶ se selecciona independientemente de hidrógeno, alquilo C₁₋₆, arilo, arilalquilo C₁₋₃, cicloalquilo C₃₋₆, halo y haloalquilo C₁₋₃; cada R⁷ se selecciona independientemente de hidrógeno, alcoxi C₁₋₃ e hidroxi; y R⁸ se selecciona de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ y alquil C₁₋₆carbonilo.
ARP130102716A 2012-07-31 2013-07-31 Inhibidores de aril lactama quinasa AR093758A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
AR093758A1 true AR093758A1 (es) 2015-06-24

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102716A AR093758A1 (es) 2012-07-31 2013-07-31 Inhibidores de aril lactama quinasa

Country Status (12)

Country Link
US (1) US8901305B2 (es)
EP (1) EP2880032B1 (es)
JP (1) JP2015528018A (es)
CN (1) CN104507941A (es)
AR (1) AR093758A1 (es)
BR (1) BR112015001890A2 (es)
CA (1) CA2880523A1 (es)
EA (1) EA201590268A1 (es)
ES (1) ES2602965T3 (es)
MX (1) MX2015000980A (es)
TW (1) TW201410676A (es)
WO (1) WO2014022167A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2693771T3 (es) * 2014-01-29 2018-12-13 Bristol-Myers Squibb Company Inhibidores de aril lactama quinasa
CA2944466C (en) * 2014-04-02 2020-06-09 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2016164295A2 (en) * 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
ES2765730T3 (es) * 2015-10-01 2020-06-10 Bristol Myers Squibb Co Inhibidores de biaril cinasa
KR102707968B1 (ko) * 2015-10-01 2024-09-20 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
CA3148504A1 (en) * 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
PT672031E (pt) 1992-12-02 2003-06-30 Pfizer Dieteres de catecol como inibidores selectivos de pde iv
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
EP1495009B1 (en) 2002-04-05 2008-03-12 Boehringer Ingelheim Pharmaceuticals Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005077363A1 (en) * 2004-02-18 2005-08-25 F. Hoffmann-La Roche Ag Heterocyclic gaba-a subtype selective receptor modulators
US20050288338A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
KR20080063833A (ko) * 2005-12-15 2008-07-07 에프. 호프만-라 로슈 아게 트리시클릭 락탐 유도체, 이의 제조 및 약학적 제제로서의용도
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
MX2008011136A (es) * 2006-03-07 2008-09-08 Squibb Bristol Myers Co Compuestos de profamarco de pirrolotriazina anilina utiles como inhibidores de cinasa.
CA2648719C (en) 2006-04-07 2015-02-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2008022154A2 (en) 2006-08-14 2008-02-21 Wyeth Methods of identifying agents for treating neurological disorders
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
WO2010132671A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
CN102918045A (zh) * 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
AU2013230128B2 (en) 2012-03-09 2017-08-17 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
WO2013134336A2 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use

Also Published As

Publication number Publication date
EP2880032B1 (en) 2016-10-05
CA2880523A1 (en) 2014-02-06
US8901305B2 (en) 2014-12-02
ES2602965T3 (es) 2017-02-23
EA201590268A1 (ru) 2015-05-29
TW201410676A (zh) 2014-03-16
US20140038999A1 (en) 2014-02-06
MX2015000980A (es) 2015-04-10
BR112015001890A2 (pt) 2017-07-04
EP2880032A1 (en) 2015-06-10
WO2014022167A1 (en) 2014-02-06
JP2015528018A (ja) 2015-09-24
CN104507941A (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR110405A1 (es) Compuestos
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097866A1 (es) Derivados de 4-azaindol
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR093515A1 (es) Triazolopirazinas
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR088630A1 (es) Inhibidores del virus de la hepatitis c
AR087909A1 (es) Composiciones farmaceuticas
AR091185A1 (es) Derivados de 1,2,4-triazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure